NO20090565L - Sammensetninger og fremgangsmater for behandling av mucormycose og andre soppsykdommer - Google Patents

Sammensetninger og fremgangsmater for behandling av mucormycose og andre soppsykdommer

Info

Publication number
NO20090565L
NO20090565L NO20090565A NO20090565A NO20090565L NO 20090565 L NO20090565 L NO 20090565L NO 20090565 A NO20090565 A NO 20090565A NO 20090565 A NO20090565 A NO 20090565A NO 20090565 L NO20090565 L NO 20090565L
Authority
NO
Norway
Prior art keywords
antifungal agent
composition
iron chelating
fungal
fungal condition
Prior art date
Application number
NO20090565A
Other languages
English (en)
Norwegian (no)
Inventor
Ashraf S Ibrahim
Brad J Spellberg
John E Edwards
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of NO20090565L publication Critical patent/NO20090565L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20090565A 2006-07-13 2009-02-05 Sammensetninger og fremgangsmater for behandling av mucormycose og andre soppsykdommer NO20090565L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27
PCT/US2007/016065 WO2008008537A2 (en) 2006-07-13 2007-07-13 Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent

Publications (1)

Publication Number Publication Date
NO20090565L true NO20090565L (no) 2009-03-30

Family

ID=38610625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090565A NO20090565L (no) 2006-07-13 2009-02-05 Sammensetninger og fremgangsmater for behandling av mucormycose og andre soppsykdommer

Country Status (18)

Country Link
US (1) US20100129434A1 (zh)
EP (2) EP2043636A2 (zh)
JP (2) JP2009543788A (zh)
KR (1) KR20090036587A (zh)
AU (1) AU2007272781B2 (zh)
BR (1) BRPI0714221A2 (zh)
CA (1) CA2657634A1 (zh)
CL (1) CL2007002026A1 (zh)
IL (1) IL196389A0 (zh)
MA (1) MA30625B1 (zh)
MX (1) MX2009000506A (zh)
NO (1) NO20090565L (zh)
NZ (1) NZ574862A (zh)
RU (1) RU2464024C2 (zh)
SG (1) SG177122A1 (zh)
TN (1) TN2009000004A1 (zh)
TW (1) TWI448285B (zh)
WO (1) WO2008008537A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110139743A (ko) * 2009-03-19 2011-12-29 로스 엔젤레스 바이오메디칼 리서치 인스티튜트 엣 하버-유씨엘에이 메디칼 센터 모균증 및 다른 진균 질환의 치료를 위한 백신 조성물 및 방법
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
MX2015003729A (es) * 2012-11-12 2015-06-15 Cipla Ltd Composiciones farmaceuticas de dosis fija que comprende deferasirox y deferiprona.
WO2014120774A1 (en) 2013-01-29 2014-08-07 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
US20160199361A1 (en) * 2013-08-19 2016-07-14 Rutgers, The State University Of New Jersey Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis
US20170239182A1 (en) * 2014-08-13 2017-08-24 Mark E. Hayes Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
WO2016025611A2 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of chelating agents as a metal removal treatment system
US11298364B2 (en) * 2015-08-31 2022-04-12 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
WO2017197386A1 (en) * 2016-05-13 2017-11-16 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
WO2020264076A1 (en) 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
DE50111949D1 (de) * 2000-12-16 2007-03-15 Alstom Technology Ltd Komponente einer Strömungsmaschine
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
JP2006513235A (ja) * 2002-12-31 2006-04-20 ネクター セラピューティクス 真菌感染症療法のためのエアゾール化可能な医薬製剤
WO2004108114A2 (en) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Anti-fungal composition and a process for its manufacture
DE10356409B4 (de) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate

Also Published As

Publication number Publication date
MA30625B1 (fr) 2009-08-03
JP2013040212A (ja) 2013-02-28
CL2007002026A1 (es) 2008-06-06
EP2412371A1 (en) 2012-02-01
US20100129434A1 (en) 2010-05-27
AU2007272781B2 (en) 2012-10-18
JP2009543788A (ja) 2009-12-10
TN2009000004A1 (en) 2010-08-19
WO2008008537A2 (en) 2008-01-17
TW200816994A (en) 2008-04-16
EP2043636A2 (en) 2009-04-08
AU2007272781A1 (en) 2008-01-17
CA2657634A1 (en) 2008-01-17
IL196389A0 (en) 2009-09-22
RU2464024C2 (ru) 2012-10-20
TWI448285B (zh) 2014-08-11
KR20090036587A (ko) 2009-04-14
RU2009104961A (ru) 2010-08-20
SG177122A1 (en) 2012-01-30
WO2008008537A3 (en) 2008-04-24
BRPI0714221A2 (pt) 2013-01-01
NZ574862A (en) 2012-02-24
MX2009000506A (es) 2009-05-20

Similar Documents

Publication Publication Date Title
NO20090565L (no) Sammensetninger og fremgangsmater for behandling av mucormycose og andre soppsykdommer
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
NO20090144L (no) Heterosykliske aspartylproteaseinhibitorer
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007127791A3 (en) New pharmacological method for treatment of neuropathic pain
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
WO2009148623A3 (en) Methods and related compositions for the treatment of cancer
NZ599906A (en) Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
GEP20237541B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
WO2010032011A3 (en) Anti-fungal therapy
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2010022236A3 (en) Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
PH12021550832A1 (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MX2019014302A (es) Agente para prevenir o tratar la ataxia espinocerebelosa.
WO2021216687A9 (en) Peptides for the treatment of covid-19
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
WO2012061767A3 (en) Defensin-like molecules as novel antimicrobial agents
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application